Skip to main content
Triangle logo TriangleGet started

Elranatamab (NCT06207799)

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma: a one-minute explainerNCT062077991 min

Elranatamab trial for Multiple Myeloma (NCT06207799). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for transplant-eligible adults aged 18–75 with newly diagnosed multiple myeloma and high-risk chromosome changes. At least a partial response to induction treatment is required.

The idea: elranatamab links BCMA-bearing myeloma cells to T cells. It is injected under the skin before stem-cell collection and after autologous transplantation, with oral maintenance lenalidomide. Researchers assess residual cancer, graft contamination, safety, and sustained disease clearance. Stem-cell collection, conditioning chemotherapy, and transplantation are part of the plan.

This phase 2 study plans 40 patients. Qaiser Bashir leads in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.